Effective March 1, 2018, new precertification requirements will go
into effect for Independence commercial and Medicare Advantage HMO and PPO
members for the following specialty drugs that are eligible for coverage under
the medical benefit:
- Durolane® (hyaluronic acid)
- IxifiTM (infliximab-qbtx)
- Lutathera (lutetium [177Lu] oxodotreotide)
- OgivriTM (trastuzumab-dkst)
- PemfexyTM (pemetrexed)
- TriViscTM (sodium hyaluronate)
These changes will be reflected in an updated precertification requirement
list, which will be posted to our
website prior to these changes going into effect. The
availability of the updated precertification list will be announced in a future
Partners in Health UpdateSM article.